Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.83 USD
Change Today -0.01 / -0.15%
Volume 549.6K
SPPI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:47 PM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

spectrum pharmaceuticals inc (SPPI) Snapshot

Open
$6.87
Previous Close
$6.84
Day High
$7.05
Day Low
$6.72
52 Week High
07/3/14 - $9.27
52 Week Low
04/30/15 - $5.45
Market Cap
457.6M
Average Volume 10 Days
849.2K
EPS TTM
$-0.59
Shares Outstanding
67.0M
EX-Date
12/18/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SPECTRUM PHARMACEUTICALS INC (SPPI)

spectrum pharmaceuticals inc (SPPI) Related Bloomberg News

View More Bloomberg News

spectrum pharmaceuticals inc (SPPI) Related Businessweek News

No Related Businessweek News Found

spectrum pharmaceuticals inc (SPPI) Details

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets five drug products, including FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and BELEODAQ injection for patients with relapsed or refractory PTCL. It is also developing Captisol-enabled MELPHALAN, an intravenous formulation for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

241 Employees
Last Reported Date: 03/13/15
Founded in 1987

spectrum pharmaceuticals inc (SPPI) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.8M
President and Chief Operating Officer
Total Annual Compensation: $880.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $675.0K
Chief Medical Officer
Total Annual Compensation: $715.0K
Compensation as of Fiscal Year 2014.

spectrum pharmaceuticals inc (SPPI) Key Developments

Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as Rapid Communication in the Journal of Clinical Oncology

Spectrum Pharmaceuticals announced the publication of results from the pivotal BELIEF (CLN-19) Study, which was selected as a Rapid Communication in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology. The study, led by Dr. Owen O’Connor from the Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, NY, showed that monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major subtypes, irrespective of the number or type of prior therapies. Beleodaq, previously known as belinostat, is a histone deacetylase (HDAC) inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor Response Rate and Duration of Response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Peripheral T-cell lymphomas are a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for relapsed or refractory patients. Unfortunately, current treatment options for most of these patients induce responses in only a minority of cases (<30%), and thus long-term survival is relatively poor. The BELIEF study evaluated the efficacy and tolerability of Beleodaq as a single agent in R/R PTCL. This study was an open-label, single-arm, non-randomized, international trial conducted at 62 centers that enrolled 129 patients with R/R PTCL, who had progressed following =1 prior therapy with a median number of prior therapies of two (1-8). These patients received Beleodaq (1,000 mg/m2) as daily 30-minute infusions on Days 1-5 every 21 days until disease progression or unacceptable toxicity. The primary endpoint of the BELIEF study was ORR as assessed centrally by an Independent Review Committee using the International Working Group (IWG) criteria. The ORR in the 120 evaluable patients was 25.8% (31 patients)(95% CI 18.3 - 34.6), including 13 Complete Responses (10.8%) (95% CI 5.9 - 17.8) and 18 Partial Responses (15%) (95% CI 9.1 - 22.7). Secondary endpoints included a median DoR of 13.6 months by IWG criteria and 8.4 months to disease progression or death, with the longest ongoing patient at =36 months. The most common Grade 3/4 adverse events were anemia (10.8%), thrombocytopenia (7%), dyspnea (6.2%), and neutropenia. No clinically relevant ECG changes were identified, and cardiovascular monitoring of ECGs is not required at baseline or during treatment. In this pivotal study, monotherapy with Beleodaq produced complete and durable responses with manageable toxicity in patients with R/R PTCL across the major disease subtypes, irrespective of the number or type of prior therapies and with a low incidence of Grade 3/4 thrombocytopenia.

Spectrum Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 10:00 AM

Spectrum Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 10:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Spectrum Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Fiscal 2015; Reports Continued Advancement of Robust, Late-Stage Pipeline

Spectrum Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues were $38.62 million against $40.12 million a year ago. Loss from operations was $21.66 million against $24.41 million a year ago. Loss before income taxes was $25.42 million against $27.56 million a year ago. Net loss was $25.56 million against $27.64 million a year ago. Diluted loss per share was $0.39 against $0.44 a year ago. Non-GAAP loss from operations was $3.803 million against income of $1.969 million a year ago. Non-GAAP net loss was $4.65 million against income of $0.691 million a year ago. Non-GAAP diluted loss per share was $0.07 against $0.01 a year ago. The company expects to exit 2015 with cash and cash equivalents of more than $100 million. The company announced significant progress in the first quarter on two potential blockbusters and two near-term NDA’s: SPI-2012, a novel long-acting GCSF: Positive Phase 2 data presented at Analyst Day, and final Phase 3 protocols have been sent to the FDA. Poziotinib, a novel pan-HER inhibitor: Compelling Phase 1 data presented in breast cancer patients who had failed multiple other HER-2 directed therapies; multiple Phase 2 studies underway. EVOMELA™(CE-Melphalan), a propylene-glycol free Melphalan with improved stability; NDA review ongoing with positive FDA discussions; on track for approval decision on October 23, 2015. Apaziquone, apotentpro-drug for non-muscle invasive bladder cancer: Statistically significant results presented from an integrated analysis of two completed Phase 3 studies; NDA submission planned in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPPI:US $6.83 USD -0.01

SPPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.22 USD +0.01
CTI BioPharma Corp $2.03 USD +0.08
GlaxoSmithKline SAE £11.50 EGP 0.00
Progenics Pharmaceuticals Inc $7.30 USD -0.16
Rigel Pharmaceuticals Inc $3.15 USD -0.0599
View Industry Companies
 

Industry Analysis

SPPI

Industry Average

Valuation SPPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRUM PHARMACEUTICALS INC, please visit www.sppirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.